Skip to main content
IAS 2023

HIV Cure & Immunotherapy Forum


The 2023 HIV Cure & Immunotherapy Forum, organized by the IAS Towards an HIV Cure initiative, will be held at the Brisbane Convention & Exhibition Centre in Brisbane, Australia, on 22 July 2023 alongside IAS 2023, the 12th IAS Conference on HIV Science. The content of the Forum will be accessible online after the meeting.

alternative text

The Forum will feature invited speakers, oral abstract discussions, a poster exhibition and a panel discussion. A networking reception will be held to facilitate further discussion.


  • Accelerate research on immunotherapy curative strategies.
  • Create an environment to foster interdisciplinary collaborations and merge the HIV cure and immunotherapy disciplines.
  • Provide an opportunity for the next generation of investigators to launch their careers through interaction and discussion with peers.
  • Promote engagement of researchers, advocates, social and behavioural scientists, ethicists, philanthropic organizations and the private sector and seek to promote research in low- and middle-income settings.
  • Promote increased investments in cure research.
  • Provide a platform for information sharing, debate and networking among peers.

Programme committee

  • Thumbi Ndung'u, Africa Health Research Institute, Durban, South Africa, co-chair
  • Beatriz Mothe Pujadas, IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Spain, co-chair
  • Anthony Kelleher, Kirby Institute, University of New South Wales, Australia co-chair
  • Heather Ellis, Positive Women Victoria, Australia
  • Sharon Lewin, Doherty Institute, Melbourne University, Australia
  • Steven Deeks, University of California San Francisco, United States


07:30 – 08:30 Registration
08:30 – 09:20 Opening
08:30 – 08:50 Welcome and Introduction

Towards an HIV Cure Initiative co-chairs:
Sharon Lewin, Australia
Thumbi Ndung’u, South Africa

Welcome from community representative:
Heather Ellis, Positive Women Victoria, Australia

Programme committee co-chairs:
Beatriz Mothe Pujadas, Spain
Thumbi Ndung’u, South Africa
Anthony Kelleher, Australia

08:50 – 09:20 Keynote
Lessons learnt from immunotherapy for autoimmunity
Ranjeny Thomas, University of Queensland, Australia
09:20 – 10:45 Session 1 – bNAbs and combination studies
09:20 – 09:25 Introduction to the session David O’Connor, University of Wisconsin-Madison, United States
09:25 – 09:45 Invited talk
Clinical trials using bNAbs
Ming Lee, Imperial College London, United Kingdom
09:45 – 10:05 Invited talk
Combination ATI trials
Michael Peluso, University of California San Francisco, United States
10:05 – 10:15 Flash talk
How to integrate reservoir measurements in ATI cure trials
Tokameh Mahmoudi, Erasmus University, The Netherlands
10:15 - 10:25 Flash talk
Clinician and participant perspectives on ATI in clinical trials
Jillian Lau, The Peter Doherty Institute, Australia
10:25 - 10:35 Oral abstract
Effect of combination latency reversing agents and bNAb in SHIV-infected rhesus macaques on antiretroviral therapy
Binhua Ling, Texas Biomedical Research Institute, United States
10:35 – 10:45 General discussion Moderator: Marina Caskey, The Rockefeller University, United States
10:45 – 11:05 Coffee break
11:05 – 12:40 Session 2 – Vaccines and immunotherapies
11:05 - 11:10 Introduction to the session Jean-Pierre Routy, McGill University, Canada
11:10 – 11:30 Invited talk
HTI T-cell vaccine clinical trials
Beatriz Mothe Pujadas, IrsiCaixa, Spain
11:30 – 11:50 Invited talk
Immunotherapies in acute cohorts
Julie Ake, US Military HIV Research Program
11:50 – 12:00 Flash talk
Immunotherapies in non-human primates
Afam Okoye, Oregon National Primate Research Center, United States
12:00 - 12:10 Flash talk
Vaccination against PD1
Zhiwei Chen, The University of Hong Kong, China
12:10 - 12:20 Oral abstract
Favourable transcriptomic signature of HIV-specific CD8 T cells in response to single anti-PD1 dose in people with HIV on ART and cancer
Jan Schroeder, Peter Doherty Institute, Australia
12:20 – 12:30 Oral abstract
Ruxolitinib-mediated HIV-1 reservoir decay in A5336 phase 2a trial
Monica D. Reece, Emory University, United States
12:30 – 12:40 General discussion Moderator: Gabriela Turk, CONICET, Argentina
12:40 – 14:00 Lunch break
14:00 – 15:15 Session 3 – Gene and cell therapy
14:00 - 14:05 Introduction to the session Chantelle Ahlenstiel, Kirby Institute, Australia
14:05 – 14:15 Flash talk
CCR5 bnAbs and monkeys
Jesse Deere, University of California, Davis, United States
14:15 – 14:25 Flash talk
R5 breakthrough after a successful CCR5-delta 32 stem cell transplant
Eli Boritz, National Institutes of Health, United States
14:25 – 14:35 Flash talk
Adeno-associated viruses (AAVs) for delivery of anti-HIV antibodies
Ann Chahroudi, Emory University, United States
14:35 - 14:45 Oral abstract
Potent, HIV-specific latency reversal through CRISPR activation delivered by lipid nanoparticles exhibiting a high efficiency of transfecting resting CD4+ T cells with minimal toxicity
Paula M. Cevaal, Peter Doherty Institute, Australia
14:45 - 14:55 Oral abstract
The Effects of HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) and Vorinostat on Persistent HIV-1 in People Living with HIV on Antiretroviral Therapy
David Michael Margolis, University of North Carolina at Chapel Hill, United States
14:55 – 15:05 Oral abstract
Engineering macaque B cells for persistent anti-HIV broadly neutralizing antibodies production
Anne-Sophie Kuhlmann, Fred Hutchinson Cancer Center, United States
15:05 – 15:15 General discussion Moderator: Kara Chew, University of California, Los Angeles, United States
15:15 – 15:35 Coffee break
15:35 – 16:40 Session 4 – Mechanisms of post-treatment and post-intervention control
15:35 - 15:40 Introduction to the session Michaela Muller-Trutwin, Institut Pasteur, France
15:40 - 15:50 Invited talk
Antigen-specific NK cells as a potential mechanism for virus control?
Keith Reeves, Duke University, United States
15:50 - 16:10 Flash talk
Mechanisms for post-intervention control
Sarah Palmer, University of Sydney, Australia
16:10 - 16:20 Flash talk
Post-treatment control in non-human primates
Shelby O’Connor, University of Wisconsin School of Medicine and Public Health, United States
16:20 - 16:30 Oral abstract
Post-treatment controllers exhibit distinct CD8+ T cell features before and after ART interruption
Tongcui Ma, Gladstone Institutes, United States
16:30 - 16:40 General discussion Moderator: Alan Landay, Rush University, United States
16:40 – 17:25 Session 5 – Panel Discussion: Community Engagement and the Importance of a Diversified Study Population for Cure Studies
16:40 - 16:45 Introduction to the session Steven Deeks, University of California San Francisco, United States
16:45 - 17:25 Panel discussion

Krista Dong, Ragon Institute, United States
Jessica Salzwedel, AVAC, United States
Tariro Makadzange, Charles River Medical Group Mutala, Zimbabwe
Ana Gabriela Pires dos Santos, AbbVie, United States
Melania Mugamu, Queensland Positive People, Australia

Steven Deeks, University of California San Francisco, United States

17:25 – 17:33 Session 6
17:25 – 17:33 Considerations on Language Use for HIV Cure Research

Michael Louella, DARE CAB, United States

Heather Ellis, Positive Women Victoria, Australia

17:33 - 17:55 Report-back session from rapporteurs
17:55 - 18:05 Closing remarks
18:05 - 19:00 Poster exhibition and networking session

Sign up to participate

To encourage the broadest participation in the pre-meeting, attendance will be free. However, the meeting will be in person only and limited to 300 attendees. Please note you may only sign up for one IAS 2023 pre-meeting.

Event at capacity and registration is closed. Add your name to the waiting list by emailing

Please note that signing up for the pre-meeting does not grant you access to IAS 2023; a separate registration is required for the main event.

See full event description here.

With support from:


The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.